New Cancer Vaccine Reduces Melanoma Recurrence Risk by 49 Percent

A combination vaccine and drug therapy has successfully reduced the risk of skin cancer recurrence and death by 49 percent in patients five years later. This development is significant because it harnesses the immune system to attack cancer cells, offering a new hope for long-term survival. The broader implication is a potential paradigm shift in oncology treatment that could drastically improve life expectancy for melanoma survivors.